Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase 2 Randomized, Open-label Study
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Cabazitaxel (Primary) ; Tocotrienols
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CaTo-ROC
- 30 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Aug 2019.
- 30 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 21 Aug 2015 New trial record